Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!
出版年份 2021 全文链接
标题
Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!
作者
关键词
Neoadjuvant trials, Immunotherapy, Melanoma, Bladder cancer, Pancreatic cancer, Head and neck cancer, PD-1, PD-L1, CTLA-4, Biomarkers
出版物
EUROPEAN JOURNAL OF CANCER
Volume 152, Issue -, Pages 155-164
出版商
Elsevier BV
发表日期
2021-06-06
DOI
10.1016/j.ejca.2021.04.035
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
- (2021) Daniel John Renouf et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
- (2021) E. A. Rozeman et al. NATURE MEDICINE
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
- (2021) Alexander M. Menzies et al. NATURE MEDICINE
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
- (2021) Tina Cascone et al. NATURE MEDICINE
- Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
- (2021) Rebekka Duhen et al. Nature Communications
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- (2021) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- (2021) Nancy Y Lee et al. LANCET ONCOLOGY
- Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment
- (2021) Annikka Weissferdt et al. LUNG CANCER
- Immune-related gene signature for predicting the prognosis of head and neck squamous cell carcinoma
- (2020) Yangyang She et al. Cancer Cell International
- Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study
- (2020) Marco Bandini et al. Clinical Genitourinary Cancer
- Top 10 Challenges in Cancer Immunotherapy
- (2020) Priti S. Hegde et al. IMMUNITY
- B cells are associated with survival and immunotherapy response in sarcoma
- (2020) Florent Petitprez et al. NATURE
- Current panorama and challenges for neoadjuvant cancer immunotherapy
- (2020) Jose Carlos BENITEZ et al. CLINICAL CANCER RESEARCH
- Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results
- (2020) Renata Ferrarotto et al. CLINICAL CANCER RESEARCH
- Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy
- (2020) Ilenia Aversa et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Lisa Zimmer et al. LANCET
- BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
- (2020) Bruno Bockorny et al. NATURE MEDICINE
- Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity
- (2020) Lauren K. Zebertavage et al. Scientific Reports
- Identification of Small Molecule Enhancers of Immunotherapy for Melanoma
- (2020) Christopher Dextras et al. Scientific Reports
- Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma
- (2020) M.T. Tetzlaff et al. ANNALS OF ONCOLOGY
- Immunotherapy for pancreatic cancer: A 2020 update
- (2020) Dimitrios Schizas et al. CANCER TREATMENT REVIEWS
- Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial
- (2020) Ravindra Uppaluri et al. CLINICAL CANCER RESEARCH
- Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer
- (2020) Andrea Necchi et al. EUROPEAN UROLOGY
- Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
- (2020) Jacqueline Vuky et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer
- (2020) Andrew Dhawan et al. Scientific Reports
- Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis
- (2020) Qi Zhang et al. Open Medicine
- Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆
- (2020) M. Bandini et al. ANNALS OF ONCOLOGY
- Association of Pathological Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-analysis
- (2020) Min Huang et al. CANCER RESEARCH
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
- (2020) Alexander M. M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
- (2020) Sean McBride et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
- (2020) Paolo A Ascierto et al. LANCET ONCOLOGY
- A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases
- (2020) Richard S. P. Huang et al. MODERN PATHOLOGY
- Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
- (2020) Nick van Dijk et al. NATURE MEDICINE
- Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis
- (2020) Ann Taber et al. Nature Communications
- Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types
- (2020) Riyue Bao et al. Genome Medicine
- Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma
- (2020) Jonathan D. Schoenfeld et al. JAMA Oncology
- Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer
- (2020) Vincent Picozzi et al. ESMO Open
- CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
- (2020) Mark H O'Hara et al. LANCET ONCOLOGY
- Clinical Decision-Making About Neoadjuvant Nivolumab Plus Ipilimumab—Reply
- (2020) Jonathan D. Schoenfeld et al. JAMA Oncology
- Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect
- (2020) Dante J. Merlino et al. Frontiers in Oncology
- Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
- (2020) Wenhua Liang et al. Translational Lung Cancer Research
- Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer
- (2020) Jonathan J. Hue et al. AMERICAN JOURNAL OF SURGERY
- A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
- (2019) Alexander C. Huang et al. NATURE MEDICINE
- TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer
- (2019) Davide Melisi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer
- (2019) Ulla Klaiber et al. ANNALS OF SURGERY
- Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts
- (2019) Mark A. Eckert et al. NATURE
- Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
- (2019) Rodabe N Amaria et al. LANCET ONCOLOGY
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
- (2019) Elisa A Rozeman et al. LANCET ONCOLOGY
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
- (2019) Alexander M.M. Eggermont et al. EUROPEAN JOURNAL OF CANCER
- Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies
- (2019) Andrea Necchi et al. EUROPEAN UROLOGY
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
- (2019) Thomas Powles et al. NATURE MEDICINE
- Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma
- (2019) Hui-Ching Wang et al. Frontiers in Oncology
- Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study
- (2019) Andrea Necchi et al. EUROPEAN UROLOGY
- Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
- (2018) M T Tetzlaff et al. ANNALS OF ONCOLOGY
- The Immune Revolution: A Case for Priming, Not Checkpoint
- (2018) Robert H. Vonderheide CANCER CELL
- Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial
- (2018) Yungan Tao et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
- (2018) Thomas Duhen et al. Nature Communications
- Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity
- (2018) Marka R. Crittenden et al. Scientific Reports
- Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma.
- (2018) Richard Bryan Bell et al. JOURNAL OF CLINICAL ONCOLOGY
- Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
- (2018) Davide Melisi et al. BRITISH JOURNAL OF CANCER
- Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy
- (2018) Michele Maio et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
- (2018) Maura L Gillison et al. LANCET
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
- (2018) Christian U. Blank et al. NATURE MEDICINE
- Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy
- (2018) Carolina Fazio et al. Frontiers in Pharmacology
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases
- (2016) Ileana S. Mauldin et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma
- (2016) Sarah Sloot et al. MELANOMA RESEARCH
- Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
- (2016) Michael B. Bernstein et al. Nature Reviews Clinical Oncology
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10
- (2015) Ileana S. Mauldin et al. INTERNATIONAL JOURNAL OF CANCER
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- KRAS: feeding pancreatic cancer proliferation
- (2014) Kirsten L. Bryant et al. TRENDS IN BIOCHEMICAL SCIENCES
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer
- (2012) Tatiana M. Prowell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now